SAM 학술관계분석서비스

논문영향력 요약
주제	egfr tki emt metastasis nf-κb nsclc tnfα complex i
466	0	0.0%

논문영향력
주제	주제별 논문수	주제별 피인용횟수	주제별 논문영향력
주제어	egfr tki	7	0	0.0%
emt	80	0	0.0%
metastasis	261	0	0.0%
nf-κb	76	0	0.0%
nsclc	42	0	0.0%
tnfα complex i	1	0	0.0%
계		467	0	0.0%
* 다른 주제어 보유 논문에서 피인용된 횟수	0

Zhao, X., R. E. Ayer, S. L. Davis, S. J. Ames, B. Florence, C. Torchinsky, J. S. Liou, L. Shen and R. A. Spanjaard. 2005. "Apoptosis factor EI24/PIG8 is a novel endoplasmic reticulum-localized Bcl-2-binding protein which is associated with suppression of breast cancer invasiveness". Cancer Res, 65(6).

Zhao, H., H. B. Grossman, M. R. Spitz, S. P. Lerner, K. Zhang and X. Wu. 2003. "Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk". J Urol, 169(2).

Zhang, Z., J. C. Lee, L. Lin, V. Olivas, V. Au, T. LaFramboise, M. Abdel-Rahman, X. Wang, A. D. Levine, J. K. Rho, Y. J. Choi, C. M. Choi, S. W. Kim, S. J. Jang, Y. S. Park, W. S. Kim, D. H. Lee, J. S. Lee, V. A. Miller, M. Arcila, M. Ladanyi, P. Moonsamy, C. Sawyers, T. J. Boggon, P. C. Ma, C. Costa, M. Taron, R. Rosell, B. Halmos and T. G. Bivona. 2012. "Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer". Nat Genet, 44(8).

Yu, M., A. Bardia, B. S. Wittner, S. L. Stott, M. E. Smas, D. T. Ting, S. J. Isakoff, J. C. Ciciliano, M. N. Wells, A. M. Shah, K. F. Concannon, M. C. Donaldson, L. V. Sequist, E. Brachtel, D. Sgroi, J. Baselga, S. Ramaswamy, M. Toner, D. A. Haber and S. Maheswaran. 2013. "Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition". Science, 339(6119).

Yu, H. A., G. J. Riely and C. M. Lovly. 2014. "Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors". Clin Cancer Res, 20(23).

Xu, L., S. S. Shen, Y. Hoshida, A. Subramanian, K. Ross, J. P. Brunet, S. N. Wagner, S. Ramaswamy, J. P. Mesirov and R. O. Hynes. 2008. "Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases". Mol Cancer Res, 6(5).

Xie, X., J. Lu, E. J. Kulbokas, T. R. Golub, V. Mootha, K. Lindblad-Toh, E. S. Lander and M. Kellis. 2005. "Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals". Nature, 434(7031).

Wertz, I. E. and V. M. Dixit. 2010. "Signaling to NF-kappaB: regulation by ubiquitination". Cold Spring Harb Perspect Biol, 2(3).

Vazquez-Martin, A., S. Cufi, C. Oliveras-Ferraros, V. Z. Torres-Garcia, B. Corominas-Faja, E. Cuyas, R. Bonavia, J. Visa, B. Martin-Castillo, E. Barrajon- Catalan, V. Micol, J. Bosch-Barrera and J. A. Menendez. 2013. "IGF-1R/epithelial-tomesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations". Sci Rep, 3.

Tsai, J. H. and J. Yang. 2013. "Epithelial-mesenchymal plasticity in carcinoma metastasis". Genes Dev, 27(20).

Tian, Y., Z. Li, W. Hu, H. Ren, E. Tian, Y. Zhao, Q. Lu, X. Huang, P. Yang, X. Li, X. Wang, A. L. Kovacs, L. Yu and H. Zhang. 2010. "C. elegans screen identifies autophagy genes specific to multicellular organisms". Cell, 141(6).

Thomson, S., F. Petti, I. Sujka-Kwok, D. Epstein and J. D. Haley. 2008. "Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy". Clin Exp Metastasis, 25(8). Tian, B., D. E. Nowak, M. Jamaluddin, S. Wang and A. R. Brasier. 2005. "Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling". J Biol Chem, 280(17).

Thomson, S., E. Buck, F. Petti, G. Griffin, E. Brown, N. Ramnarine, K. K. Iwata, N. Gibson and J. D. Haley. 2005. "Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition". Cancer Res, 65(20).

Thiery, J. P. and J. P. Sleeman. 2006. "Complex networks orchestrate epithelialmesenchymal transitions". Nat Rev Mol Cell Biol, 7(2).

Taube, J. H., J. I. Herschkowitz, K. Komurov, A. Y. Zhou, S. Gupta, J. Yang, K. Hartwell, T. T. Onder, P. B. Gupta, K. W. Evans, B. G. Hollier, P. T. Ram, E. S. Lander, J. M. Rosen, R. A. Weinberg and S. A. Mani. 2010. "Core epithelial-tomesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes". Proc Natl Acad Sci U S A, 107(35).

Tada, K., T. Okazaki, S. Sakon, T. Kobarai, K. Kurosawa, S. Yamaoka, H. Hashimoto, T. W. Mak, H. Yagita, K. Okumura, W. C. Yeh and H. Nakano. 2001. "Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death". J Biol Chem, 276(39).

Symmans, W. F., C. Hatzis, C. Sotiriou, F. Andre, F. Peintinger, P. Regitnig, G. Daxenbichler, C. Desmedt, J. Domont, C. Marth, S. Delaloge, T. Bauernhofer, V. Valero, D. J. Booser, G. N. Hortobagyi and L. Pusztai. 2010. "Genomic index of sensitivity to endocrine therapy for breast cancer". J Clin Oncol, 28(27).

Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander and J. P. Mesirov. 2005. "Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles". Proc Natl Acad Sci U S A, 102(43).

Sinha, S., R. K. Singh, N. Bhattacharya, N. Mukherjee, S. Ghosh, N. Alam, A. Roy, S. Roychoudhury and C. K. Panda. 2011. "Frequent alterations of LOH11CR2A, PIG8 and CHEK1 genes at chromosomal 11q24.1-24.2 region in breast carcinoma: clinical and prognostic implications". Mol Oncol, 5(5).

Sharma, S. V., D. Y. Lee, B. Li, M. P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M. A. Fischbach, K. K. Wong, K. Brandstetter, B. Wittner, S. Ramaswamy, M. Classon and J. Settleman. 2010. "A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations". Cell, 141(1).

Schwitalla, S., P. K. Ziegler, D. Horst, V. Becker, I. Kerle, Y. Begus-Nahrmann, A. Lechel, K. L. Rudolph, R. Langer, J. Slotta-Huspenina, F. G. Bader, O. Prazeres da Costa, M. F. Neurath, A. Meining, T. Kirchner and F. R. Greten. 2013. "Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors". Cancer Cell, 23(1).

Rinaldi, S., P. H. Peeters, F. Berrino, L. Dossus, C. Biessy, A. Olsen, A. Tjonneland, K. Overvad, F. Clavel-Chapelon, M. C. Boutron-Ruault, B. Tehard, G. Nagel, J. Linseisen, H. Boeing, P. H. Lahmann, A. Trichopoulou, D. Trichopoulos, M. Koliva, D. Palli, S. Panico, R. Tumino, C. Sacerdote, C. H. van Gils, P. van Noord, D. E. Grobbee, H. B. Bueno-de-Mesquita, C. A. Gonzalez, A. Agudo, M. D. Chirlaque, A. Barricarte, N. Larranaga, J. R. Quiros, S. Bingham, K. T. Khaw, T. Key, N. E. Allen, A. Lukanova, N. Slimani, R. Saracci, E. Riboli and R. Kaaks. 2006. "IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC)". Endocr Relat Cancer, 13(2).

Rhodes, D. R., J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey and A. M. Chinnaiyan. 2004. "ONCOMINE: a cancer microarray database and integrated data-mining platform". Neoplasia, 6(1).

Rho, J. K., Y. J. Choi, J. K. Lee, B. Y. Ryoo, Na, II, S. H. Yang, C. H. Kim and J. C. Lee. 2009. "Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line". Lung Cancer, 63(2).

Qi, H. W., Z. Shen and L. H. Fan. 2011. "Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line". Exp Ther Med, 2(6).

Pollak, M. 2008. "Insulin and insulin-like growth factor signalling in neoplasia". Nat Rev Cancer, 8(12).

Parsons, J. T., A. R. Horwitz and M. A. Schwartz. 2010. "Cell adhesion: integrating cytoskeletal dynamics and cellular tension". Nat Rev Mol Cell Biol, 11(9).

Park, K. S., M. Raffeld, Y. W. Moon, L. Xi, C. Bianco, T. Pham, L. C. Lee, T. Mitsudomi, Y. Yatabe, I. Okamoto, D. Subramaniam, T. Mok, R. Rosell, J. Luo, D. S. Salomon, Y. Wang and G. Giaccone. 2014. "CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance". J Clin Invest, 124(7).

Pao, W. and J. Chmielecki. 2010. "Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer". Nat Rev Cancer, 10(11).

Oeckinghaus, A., M. S. Hayden and S. Ghosh. 2011. "Crosstalk in NF-kappaB signaling pathways". Nat Immunol, 12(8).

Nicolson, G. L., K. W. Brunson and I. J. Fidler. 1978. "Specificity of arrest, survival, and growth of selected metastatic variant cell lines". Cancer Res, 38(11 Pt 2).

Murakami, A., F. Takahashi, F. Nurwidya, I. Kobayashi, K. Minakata, M. Hashimoto, T. Nara, M. Kato, K. Tajima, N. Shimada, S. Iwakami, M. Moriyama, H. Moriyama, F. Koizumi and K. Takahashi. 2014. "Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor". PLoS One, 9(1).

Moffat, J., D. A. Grueneberg, X. Yang, S. Y. Kim, A. M. Kloepfer, G. Hinkle, B. Piqani, T. M. Eisenhaure, B. Luo, J. K. Grenier, A. E. Carpenter, S. Y. Foo, S. A. Stewart, B. R. Stockwell, N. Hacohen, W. C. Hahn, E. S. Lander, D. M. Sabatini and D. E. Root. 2006. "A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen". Cell, 124(6).

Minn, A. J., G. P. Gupta, P. M. Siegel, P. D. Bos, W. Shu, D. D. Giri, A. Viale, A. B. Olshen, W. L. Gerald and J. Massague. 2005. "Genes that mediate breast cancer metastasis to lung". Nature, 436(7050).

Min, C., S. F. Eddy, D. H. Sherr and G. E. Sonenshein. 2008. "NF-kappaB and epithelial to mesenchymal transition of cancer". J Cell Biochem, 104(3).

Mazumder Indra, D., S. Mitra, R. K. Singh, S. Dutta, A. Roy, R. K. Mondal, P. S. Basu, S. Roychoudhury and C. K. Panda. 2011. "Inactivation of CHEK1 and EI24 is associated with the development of invasive cervical carcinoma: clinical and prognostic implications". Int J Cancer, 129(8).

Massoner, P., M. Ladurner-Rennau, I. E. Eder and H. Klocker. 2010. "Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer". Br J Cancer, 103(10).

Mantovani, A. 2010. "Molecular pathways linking inflammation and cancer". Curr Mol Med, 10(4).

Mani, S. A., W. Guo, M. J. Liao, E. N. Eaton, A. Ayyanan, A. Y. Zhou, M. Brooks, F. Reinhard, C. C. Zhang, M. Shipitsin, L. L. Campbell, K. Polyak, C. Brisken, J. Yang and R. A. Weinberg. 2008. "The epithelial-mesenchymal transition generates cells with properties of stem cells". Cell, 133(4).

Loi, S., B. Haibe-Kains, C. Desmedt, P. Wirapati, F. Lallemand, A. M. Tutt, C. Gillet, P. Ellis, K. Ryder, J. F. Reid, M. G. Daidone, M. A. Pierotti, E. M. Berns, M. P. Jansen, J. A. Foekens, M. Delorenzi, G. Bontempi, M. J. Piccart and C. Sotiriou. 2008. "Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen". BMC Genomics, 9.

Loi, S., B. Haibe-Kains, C. Desmedt, F. Lallemand, A. M. Tutt, C. Gillet, P. Ellis, A. Harris, J. Bergh, J. A. Foekens, J. G. Klijn, D. Larsimont, M. Buyse, G. Bontempi, M. Delorenzi, M. J. Piccart and C. Sotiriou. 2007. "Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade". J Clin Oncol, 25(10).

Lee, J., A. Jain, P. Kim, T. Lee, A. Kuller, F. Princen, G. In, S. H. Kim, J. O. Park, Y. S. Park, S. Singh and H. C. Kim. 2014. "Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status". PLoS One, 9(8).

Kim, S. M., O. J. Kwon, Y. K. Hong, J. H. Kim, F. Solca, S. J. Ha, R. A. Soo, J. G. Christensen, J. H. Lee and B. C. Cho. 2012. "Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation". Mol Cancer Ther, 11(10).

Kim, S. M., J. S. Kim, J. H. Kim, C. O. Yun, E. M. Kim, H. K. Kim, F. Solca, S. Y. Choi and B. C. Cho. 2010. "Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells". Cancer Lett, 296(2).

Khandwala, H. M., I. E. McCutcheon, A. Flyvbjerg and K. E. Friend. 2000. "The effects of insulin-like growth factors on tumorigenesis and neoplastic growth". Endocr Rev, 21(3).

Karin, M. and F. R. Greten. 2005. "NF-kappaB: linking inflammation and immunity to cancer development and progression". Nat Rev Immunol, 5(10).

Kang, Y., P. M. Siegel, W. Shu, M. Drobnjak, S. M. Kakonen, C. Cordon-Cardo, T. A. Guise and J. Massague. 2003. "A multigenic program mediating breast cancer metastasis to bone". Cancer Cell, 3(6).

Ji, H., D. Li, L. Chen, T. Shimamura, S. Kobayashi, K. McNamara, U. Mahmood, A. Mitchell, Y. Sun, R. Al-Hashem, L. R. Chirieac, R. Padera, R. T. Bronson, W. Kim, P. A. Janne, G. I. Shapiro, D. Tenen, B. E. Johnson, R. Weissleder, N. E. Sharpless and K. K. Wong. 2006. "The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies". Cancer Cell, 9(6).

Jechlinger, M., S. Grunert, I. H. Tamir, E. Janda, S. Ludemann, T. Waerner, P. Seither, A. Weith, H. Beug and N. Kraut. 2003. "Expression profiling of epithelial plasticity in tumor progression". Oncogene, 22(46).

Jang, K. W., K. H. Lee, S. H. Kim, T. Jin, E. Y. Choi, H. J. Jeon, E. Kim, Y. S. Han and J. H. Chung. 2011. "Ubiquitin ligase CHIP induces TRAF2 proteasomal degradation and NF-kappaB inactivation to regulate breast cancer cell invasion". J Cell Biochem, 112(12).

Jackman, D., W. Pao, G. J. Riely, J. A. Engelman, M. G. Kris, P. A. Janne, T. Lynch, B. E. Johnson and V. A. Miller. 2010. "Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer". J Clin Oncol, 28(2).

Izumchenko, E., X. Chang, C. Michailidi, L. Kagohara, R. Ravi, K. Paz, M. Brait, M. O. Hoque, S. Ling, A. Bedi and D. Sidransky. 2014. "The TGFbeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors". Cancer Res, 74(14).

Huber, M. A., N. Azoitei, B. Baumann, S. Grunert, A. Sommer, H. Pehamberger, N. Kraut, H. Beug and T. Wirth. 2004. "NF-kappaB is essential for epithelialmesenchymal transition and metastasis in a model of breast cancer progression". J Clin Invest, 114(4).

Horst, D., J. Budczies, T. Brabletz, T. Kirchner and F. Hlubek. 2009. "Invasion associated up-regulation of nuclear factor kappaB target genes in colorectal cancer". Cancer, 115(21).

Hood, J. D. and D. A. Cheresh. 2002. "Role of integrins in cell invasion and migration". Nat Rev Cancer, 2(2).

Heidegger, I., A. Pircher, H. Klocker and P. Massoner. 2011. "Targeting the insulinlike growth factor network in cancer therapy". Cancer Biol Ther, 11(8).

Harhaj, E. W. and V. M. Dixit. 2011. "Deubiquitinases in the regulation of NF-kappaB signaling". Cell Res, 21(1).

Gyorffy, B., A. Lanczky, A. C. Eklund, C. Denkert, J. Budczies, Q. Li and Z. Szallasi. 2010. "An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients". Breast Cancer Res Treat, 123(3).

Gupta, G. P. and J. Massague. 2006. "Cancer metastasis: building a framework". Cell, 127(4).

Guo, W., M. L. Wise, F. W. Collins and M. Meydani. 2008. "Avenanthramides, polyphenols from oats, inhibit IL-1beta-induced NF-kappaB activation in endothelial cells". Free Radic Biol Med, 44(3).

Guix, M., A. C. Faber, S. E. Wang, M. G. Olivares, Y. Song, S. Qu, C. Rinehart, B. Seidel, D. Yee, C. L. Arteaga and J. A. Engelman. 2008. "Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins". J Clin Invest, 118(7).

Gu, Z., C. Flemington, T. Chittenden and G. P. Zambetti. 2000. "ei24, a p53 response gene involved in growth suppression and apoptosis". Mol Cell Biol, 20(1).

Grivennikov, S. I., F. R. Greten and M. Karin. 2010. "Immunity, inflammation, and cancer". Cell, 140(6).

Gravdal, K., O. J. Halvorsen, S. A. Haukaas and L. A. Akslen. 2007. "A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer". Clin Cancer Res, 13(23).

Gluck, S., J. S. Ross, M. Royce, E. F. McKenna, Jr., C. M. Perou, E. Avisar and L. Wu. 2012. "TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/- trastuzumab". Breast Cancer Res Treat, 132(3).

Garcia-Echeverria, C. 2006. "Medicinal chemistry approaches to target the kinase activity of IGF-1R". IDrugs, 9(6).

Furstenberger, G. and H. J. Senn. 2002. "Insulin-like growth factors and cancer". Lancet Oncol, 3(5).

Fidler, I. J. 2003. "The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited". Nat Rev Cancer, 3(6).

Ferlay, J., I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. M. Parkin, D. Forman and F. Bray. 2014. "Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012". Int J Cancer.

Feng, Z. 2010. "p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment". Cold Spring Harb Perspect Biol, 2(2).

Ercan, D., C. Xu, M. Yanagita, C. S. Monast, C. A. Pratilas, J. Montero, M. Butaney, T. Shimamura, L. Sholl, E. V. Ivanova, M. Tadi, A. Rogers, C. Repellin, M. Capelletti, O. Maertens, E. M. Goetz, A. Letai, L. A. Garraway, M. J. Lazzara, N. Rosen, N. S. Gray, K. K. Wong and P. A. Janne. 2012. "Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors". Cancer Discov, 2(10).

Dufourny, B., J. Alblas, H. A. van Teeffelen, F. M. van Schaik, B. van der Burg, P. H. Steenbergh and J. S. Sussenbach. 1997. "Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase". J Biol Chem, 272(49).

Devkota, S., Y. H. Sung, J. M. Choi, J. Lee, N. Y. Ha, H. Kim, B. C. Cho, J. Song and H. W. Lee. 2012. "Ei24-deficiency attenuates protein kinase Calpha signaling and skin carcinogenesis in mice". Int J Biochem Cell Biol, 44(11).

Desgrosellier, J. S. and D. A. Cheresh. 2010. "Integrins in cancer: biological implications and therapeutic opportunities". Nat Rev Cancer, 10(1).

De Craene, B. and G. Berx. 2013. "Regulatory networks defining EMT during cancer initiation and progression". Nat Rev Cancer, 13(2).

Curtis, C., S. P. Shah, S. F. Chin, G. Turashvili, O. M. Rueda, M. J. Dunning, D. Speed, A. G. Lynch, S. Samarajiwa, Y. Yuan, S. Graf, G. Ha, G. Haffari, A. Bashashati, R. Russell, S. McKinney, A. Langerod, A. Green, E. Provenzano, G. Wishart, S. Pinder, P. Watson, F. Markowetz, L. Murphy, I. Ellis, A. Purushotham, A. L. Borresen-Dale, J. D. Brenton, S. Tavare, C. Caldas and S. Aparicio. 2012. "The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups". Nature, 486(7403).

Cortot, A. B., C. E. Repellin, T. Shimamura, M. Capelletti, K. Zejnullahu, D. Ercan, J. G. Christensen, K. K. Wong, N. S. Gray and P. A. Janne. 2013. "Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway". Cancer Res, 73(2).

Cohen, S. J., C. J. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath, N. Y. Gabrail, J. Picus, M. Morse, E. Mitchell, M. C. Miller, G. V. Doyle, H. Tissing, L. W. Terstappen and N. J. Meropol. 2008. "Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer". J Clin Oncol, 26(19).

Chung, J. H., J. K. Rho, X. Xu, J. S. Lee, H. I. Yoon, C. T. Lee, Y. J. Choi, H. R. Kim, C. H. Kim and J. C. Lee. 2011. "Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs". Lung Cancer, 73(2).

Chou, Y. T., H. H. Lin, Y. C. Lien, Y. H. Wang, C. F. Hong, Y. R. Kao, S. C. Lin, Y. C. Chang, S. Y. Lin, S. J. Chen, H. C. Chen, S. D. Yeh and C. W. Wu. 2010. "EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF". Cancer Res, 70(21).

Choi, S. I., S. Y. Kim, J. Lee, E. W. Cho and I. G. Kim. 2014. "TM4SF4 overexpression in radiation-resistant lung carcinoma cells activates IGF1R via elevation of IGF1". Oncotarget, 5(20).

Choi, J. M., S. Devkota, Y. H. Sung and H. W. Lee. 2013. "EI24 regulates epithelial-tomesenchymal transition and tumor progression by suppressing TRAF2-mediated NFkappaB activity". Oncotarget, 4(12).

Chen, B., F. Xiao, B. Li, B. Xie, J. Zhou, J. Zheng and W. Zhang. 2013a. "The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced nonsmall-cell lung cancer". Cancer Invest, 31(7).

Chen, B. B., T. A. Coon, J. R. Glasser, B. J. McVerry, J. Zhao, Y. Zhao, C. Zou, B. Ellis, F. C. Sciurba, Y. Zhang and R. K. Mallampalli. 2013b. "A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation". Nat Immunol, 14(5).

Chang, C. J., C. H. Chao, W. Xia, J. Y. Yang, Y. Xiong, C. W. Li, W. H. Yu, S. K. Rehman, J. L. Hsu, H. H. Lee, M. Liu, C. T. Chen, D. Yu and M. C. Hung. 2011. "p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs". Nat Cell Biol, 13(3).

Chambers, A. F., A. C. Groom and I. C. MacDonald. 2002. "Dissemination and growth of cancer cells in metastatic sites". Nat Rev Cancer, 2(8).

Chakravarti, A., J. S. Loeffler and N. J. Dyson. 2002. "Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3- kinase signaling". Cancer Res, 62(1).

Buchheit, C. L., K. J. Weigel and Z. T. Schafer. 2014. "Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression". Nat Rev Cancer, 14(9).

Brabletz, T. 2012. "EMT and MET in metastasis: where are the cancer stem cells?". Cancer Cell, 22(6).

Bos, P. D., X. H. Zhang, C. Nadal, W. Shu, R. R. Gomis, D. X. Nguyen, A. J. Minn, M. J. van de Vijver, W. L. Gerald, J. A. Foekens and J. Massague. 2009. "Genes that mediate breast cancer metastasis to the brain". Nature, 459(7249).

Blick, T., E. Widodo, H. Hugo, M. Waltham, M. E. Lenburg, R. M. Neve and E. W. Thompson. 2008. "Epithelial mesenchymal transition traits in human breast cancer cell lines". Clin Exp Metastasis, 25(6).

Blakesley, V. A., B. S. Stannard, T. Kalebic, L. J. Helman and D. LeRoith. 1997. "Role of the IGF-I receptor in mutagenesis and tumor promotion". J Endocrinol, 152(3).

Baxter, R. C. 2014. "IGF binding proteins in cancer: mechanistic and clinical insights". Nat Rev Cancer, 14(5).

Baud, V., Z. G. Liu, B. Bennett, N. Suzuki, Y. Xia and M. Karin. 1999. "Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain". Genes Dev, 13(10).

Bahr, C. and B. Groner. 2004. "The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy". Growth Horm IGF Res, 14(4).

?Alvarez, S. E., K. B. Harikumar, N. C. Hait, J. Allegood, G. M. Strub, E. Y. Kim, M. Maceyka, H. Jiang, C. Luo, T. Kordula, S. Milstien and S. Spiegel. 2010. "Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2". Nature, 465(7301).

EI24에 의한 암의 전이, 항암 내성 조절에 대한 연구

유사주제 논문( 461)

' EI24에 의한 암의 전이, 항암 내성 조절에 대한 연구' 의 주제별 논문영향력

주제별 논문영향력

' EI24에 의한 암의 전이, 항암 내성 조절에 대한 연구' 의 참고문헌

' EI24에 의한 암의 전이, 항암 내성 조절에 대한 연구' 의 유사주제( ) 논문